Form 4 for GNLX GENELUX Corp
Accepted 2025-08-29 00:00:00 ET · period of report 2025-08-27 · accession 0001641172-25-026001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-29 | 2025-08-27 | GNLX | Yu Yong | SVP, Clinical Development | A - Grant | $0.00 | +101.5K | 150.0K | +209% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Yu Yong | SVP, Clinical Development | A - Grant | $0.00 | +134.5K | 134.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-27 | A | A | 101,480 | $0.00 | 150,036 | D | — | — | (F2) Includes 916 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-08-27 | A | A | 134,520 | $0.00 | 134,520 | D | $3.64 · — to 2035-08-26 | 134,520 Common stock | (F3) The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter. |